CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 23.04×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.97BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.29xvs all stocks
52-Week Change
47.23%vs all stocks
Market Capitalization
1.97BUSDvs all stocks (USD)
Enterprise Value
1.54BUSDvs all stocks (USD)
Forward P/E
-14.57xvs Biotechnology peers
Price to Book (MRQ)
6.86xvs Biotechnology peers
Enterprise to EBITDA
-23.13xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-13.99%vs Biotechnology peers
Return on Equity (TTM)
-19.67%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-66.58MUSDvs all stocks (USD)
Net Income (TTM)
-56.41MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-45.65MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-32.74MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-60.68MUSDvs all stocks (USD)
Pre-tax Income
-48.26MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-48.26MUSDFY2025 · Dec 31, 2025EBIT
-48.22MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-55.69MUSDFY2025 · Dec 31, 2025Research & Development
38.77MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
21.65MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.08MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
35.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.7900USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.7900USDFY2025 · Dec 31, 2025Basic Shares Outstanding
61.04MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
61.04MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-48.26MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-50.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
246.25MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-48.26MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
335.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-10.66MUSDFY2025 · Dec 31, 2025Capital Expenditures
-121.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
46.29MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
46.17MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-197.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-10.15MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
139.65MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.05MSharesUpdated Jul 19, 2026Float Shares
26.72MSharesUpdated Jul 19, 2026Shares Short
1.94MSharesUpdated Jul 19, 2026Short Ratio
7.04daysvs all stocks
Short % of Shares Outstanding
7.21%vs all stocks
% Held by Insiders
24.23%vs all stocks
% Held by Institutions
70.22%vs all stocks
Total Cash (MRQ)
267.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.31USDUpdated Jul 19, 2026Total Debt (MRQ)
432.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0016xvs Biotechnology peers
Current Ratio (MRQ)
23.04xvs Biotechnology peers
Book Value per Share (MRQ)
4.25USDUpdated Jul 19, 2026Total Assets
288.23MUSDvs all stocks (USD)
Total Current Assets
285.98MUSDFY2025 · Dec 31, 2025Total Liabilities
8.53MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.25MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
147.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
8.38MUSDFY2025 · Dec 31, 2025Cash
30.97MUSDFY2025 · Dec 31, 2025Cash Equivalents
215.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
246.25MUSDFY2025 · Dec 31, 2025Other Short-term Investments
34.46MUSDFY2025 · Dec 31, 2025Accounts Payable
3.77MUSDFY2025 · Dec 31, 2025Short-term Debt
365.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
407.00KUSDFY2025 · Dec 31, 2025Long-term Debt
147.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.55MUSDFY2025 · Dec 31, 2025Retained Earnings
-154.43MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
279.70MUSDvs all stocks (USD)
52-Week Low
11.32USDUpdated Jul 19, 202652-Week High
31.00USDUpdated Jul 19, 202652-Week Change
47.23%vs all stocks
Beta
1.29xvs all stocks
50-Day MA
23.53USDUpdated Jul 19, 2026200-Day MA
17.13USDUpdated Jul 19, 2026Avg 10-Day Volume
317.52KSharesUpdated Jul 19, 2026Avg 30-Day Volume
282.44KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9100USDUpdated Jul 19, 2026Other Income / Expense
7.80MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 23.04×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 23.04Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.97B, above the global median of $1.15BNotable
Market cap (USD): 1,969,762,064Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Ocular Therapeutix Inc.
Tier 1ProductionApproval-Gated PipelineRule
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
King Slide Works Co., Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Jiangsu Hengli Hydraulic Co., Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Collective Mining Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets